<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196205</url>
  </required_header>
  <id_info>
    <org_study_id>2018027</org_study_id>
    <nct_id>NCT04196205</nct_id>
  </id_info>
  <brief_title>Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas</brief_title>
  <official_title>Study Evaluating the Safety and Efficacy With Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Nanchang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, single center study to determine the safety and efficacy of
      Anti-CD19 CAR-T cells in patients with relapsed or refractory acute lymphoblastic leukemia
      and Lymphomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CD19 has been extensively evaluated as a therapeutic target for relapsed or refractory B cell
      malignancy by chimeric antigen receptor T cell therapy,this is a single arm, open-label,
      single center study to determine the safety and efficacy of Anti-CD19 CAR-T cells in patients
      with refractory acute lymphoblastic leukemia and Lymphomas.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall responce rate(ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of ORR (ORR = CR+PR ) at 2 months of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of OS(Overall survival) at 6 months of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of PFS(Progression-free survival ) at 6 months of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>minimal residual disease（MRD）</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of MRD negative overall response rate at 3 months of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (incidence of adverse events defined as dose-limited toxicity)</measure>
    <time_frame>Study treatment until Week 24</time_frame>
    <description>Occurrence of study related adverse events defined as NCI CTCAE 4.0 &gt; grade 3 possibly, probably, or definitely related to study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of CD19 CART cells</measure>
    <time_frame>2 years</time_frame>
    <description>Expression of CD19 CART cells detected by flow cytometry in blood and bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of CD19 CART cells</measure>
    <time_frame>2 years</time_frame>
    <description>Detection of CD19 CART cells in blood, bone marrow by Quantitative Polymerase Chain Reaction (q-PCR).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Lymphoblastic Leukemia ,Lymphomas</condition>
  <arm_group>
    <arm_group_label>Anti-CD19 CAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-CD19 CAR-T</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-CD19 CAR-T</intervention_name>
    <description>1 - 2×10^6 Anti-CD19 CAR-T cells/kg body weigh</description>
    <arm_group_label>Anti-CD19 CAR-T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Subjects diagnosed as Relapsed or Refractory acute lymphoblastic
        leukemia and Lymphomas ，and have no effective treatment option (such as autograft or
        allogeneic stem cell transplantation) and estimated survival time of the current treatment
        &lt; 2 years, The specific requirements are as follows:

          1. Male or female aged 18-70 years old ;

          2. Estimated Survival time &gt; 12 weeks;

          3. Relapsed and refractory acute lymphoblastic leukemia and lymphoma were confirmed by
             physical examination, pathological examination, laboratory examination and imaging;

          4. Chemotherapy failure or recurrent acute lymphoblastic leukemia and Lymphomas;

          5. Glutamic-pyruvic transaminase, glutamic oxalacetic transaminase&lt; 3 fold of normal
             level;

          6. Bilirubin&lt;2.0mg/dl;

          7. Karnofsky Performance Status&gt;50% at the time of screening;

          8. Adequate pulmonary, renal, hepatic, and cardiac function;

          9. Fail in autologous or allogenic haemopoietic stem cell transplantation;

         10. Not suitable for stem cell transplantation conditions or abandoned due to conditions;

         11. Free of leukocytes removal contraindications;

         12. Voluntarily join CAR-T clinical trial ,Understand and sign written informed consent.

        Exclusion Criteria:

          1. The patient is a pregnant or breastfeeding woman, or is a woman with a pregnancy plan
             within six months;

          2. Patients have infectious diseases (such as HIV, active tuberculosis, etc.);

          3. The patient is an active hepatitis B or hepatitis C infection;

          4. Feasibility assessment proves that the efficiency of transduction of lymphocyte is
             below 10% or the lymphocyte cannot be propagated ;

          5. Abnormal vital signs;

          6. Subjects with mental or psychological illness who cannot be combined with treatment
             and efficacy evaluation;

          7. Highly allergic constitution or history of severe allergies, especially allergy to
             interleukin-2;

          8. General infection or local severe infection, or other infection that is not
             controlled;

          9. Dysfunction in lung, heart, kidney and brain;

         10. Severe autoimmune diseases;

         11. Other symptoms that are not applicable for CAR-T.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fei Li, M.D., Ph.D.</last_name>
    <phone>+86-139-7003-8386</phone>
    <email>yx021021@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nangchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei Li, M.D., Ph.D.</last_name>
      <phone>+86-139-7003-8386</phone>
      <email>yx021021@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Nanchang University</investigator_affiliation>
    <investigator_full_name>LiFei</investigator_full_name>
    <investigator_title>M.D.,Ph.D.</investigator_title>
  </responsible_party>
  <keyword>acute lymphoblastic leukemia ;Lymphomas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

